CIK 0001321834
- Non-accelerated filer
- Smaller reporting company
Q/C TECHNOLOGIES, INC.
Sign in to watch- Ticker
- QCLS
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 856-848-8698
- Business address
- 1185 AVENUE OF THE AMERICAS, SUITE 249, NEW YORK, NY, 10036
- Former names
- Q/C TECHNOLOGIES, INC., TNF Pharmaceuticals, Inc., MyMD Pharmaceuticals, Inc., Akers Biosciences, Inc., Akers Biosciences Inc
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-06-07 | Kaplin Adam Chief Scientific Officer | Grant or award · Employee Stock Option (Right to Buy) | +150,000 | 150,000 | ||
| 2021-10-14 | Kaplin Adam Chief Scientific Officer | Grant or award · Restricted Stock Units | +600,000 | 600,000 | ||
| 2021-04-16 | Kaplin Adam Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +154,360 | 154,360 |
Page 1 of 1 · 3 trades